#None #Berlin #OncoHost #PROphet #ESMO

OncoHost's Innovative Research on Melanoma Treatment

OncoHost, a leading technology company in precision medicine, will present its latest findings at the European Society for Medical Oncology (ESMO) Congress 2025, which takes place from October 17 to 21 in Berlin, Germany. The focus of their research revolves around a plasma proteomics-based model specifically geared towards optimizing first-line treatment decisions for metastatic melanoma.

The study, titled A Plasma Proteomics-Based Model Optimizes First-Line Treatment Decisions for Metastatic Melanoma, aims to integrate the PROphet® model—originally designed for non-small cell lung cancer (NSCLC)—into melanoma treatment protocols, addressing the challenges presented by the limited availability of biomarkers in this field.

The poster presentation is scheduled for October 18, 2025, with Dr. Ryan Sullivan of Massachusetts General Hospital leading the session. As melanoma becomes an increasingly urgent health concern, this research seeks to provide clearer pathways for treatment based on individual patient profiles, which is essential for enhancing patient outcomes in oncology.

Key Findings and Insights

The PROphet® platform utilizes a sophisticated analysis involving a panel of 388 Resistance-Associated Proteins (RAPs). This model not only computes the probability of clinical benefit (CB) for patients but also classifies them into PROphet POSITIVE or PROphet NEGATIVE categories. Prior studies in NSCLC have demonstrated the model’s predictive capabilities, offering vital insights into patient responses to anti–PD(L)1-based therapies.

In this study, data from 248 patients with metastatic melanoma who were treated with either anti-PD1 monotherapy (including pembrolizumab or nivolumab) or a combination of anti-PD1 and anti-CTLA4 therapy (ipilimumab + nivolumab) were analyzed. Some of the most notable findings are summarized below:

• - Prognostic Power: The PROphet® model effectively stratified melanoma patients, showcasing that PROphet POSITIVE individuals experienced a significantly improved survival rate compared to their PROphet NEGATIVE counterparts (HR = 0.42, p < 0.001).
• - Predictive for Anti-PD1 Therapy: Enhanced predictive accuracy was particularly pronounced among patients receiving anti-PD1 monotherapy, solidifying the model’s relevance in treatment decision-making.
• - Independent Factor: In multivariate analysis, PROphet® remained a significant predictor even when accounting for variables like LDH, age, sex, and more (HR = 0.30, p = 0.04).

Treatment Guidance and Implications

Patients categorized as PROphet POSITIVE (66% of the studied cohort) reached comparable survival outcomes when treated with anti-PD1 monotherapy versus combination therapies (HR = 0.9, p = 0.35). This result indicates that for this group, immunotherapy alone may suffice, thereby preventing potential toxicity associated with more aggressive combination regimens. Conversely, those classified as PROphet NEGATIVE displayed a notable trend towards enhanced survival with combination treatment (HR = 0.64, p = 0.065).

Dr. Michal Harel, VP of Translational Medicine at OncoHost, shared the significance of their findings, stating, “Selecting the appropriate treatment for melanoma patients is a complex clinical hurdle. Our results illustrate how plasma proteomics can empower actionable insights for treatment decisions, moving us closer to truly personalized patient care in the melanoma arena.”

About OncoHost

Based in Binyamina, Israel, and Cary, North Carolina, OncoHost is at the forefront of advancing precision medicine aimed at optimizing cancer treatment outcomes. The PROphet® platform is an innovative, plasma-based proteomic analysis tool that has shown profound clinical utility in guiding first-line immunotherapy decisions in NSCLC. Its successful implementation is backed by rigorous prospective clinical trials that have recruited over 1,700 patients across more than 40 sites globally.

For further insights and updates about their groundbreaking work, visit OncoHost’s website or connect with them on social media platforms, including LinkedIn, Twitter, Facebook, and YouTube.